Camillo Guglielmo Porta, MD, University of Bari Aldo Moro, Bari, Italy, provides an overview of current advances in novel targeted therapies for renal cell carcinoma (RCC), including the latest in tyrosine kinase inhibitors (TKIs) for kidney cancer. Prof. Porta additionally highlights belzutifan, a HIF-2α inhibitor, as a potential targeted therapy for RCC, especially in combination therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.